Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib versus methotrexate for morphea
IRCT20250102064248N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in morphea comparing Tofacitinib arm with Methotrexate control arm (2 arms). Primary endpoints: Addition of new treatments to morphea disease and Avoiding the side effects of methotrexate and replacing it with a new drug. Started Jan 2025; status: completed.
02
Drugs
tofacitinibmethotrexate
03
Conditions
morphea
Beyond the preview
Go deeper on IRCT20250102064248N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250102064248N1.